Prudential Financial Inc. raised its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 5.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,660 shares of the biopharmaceutical company’s stock after buying an additional 200 shares during the period. Prudential Financial Inc.’s holdings in Ultragenyx Pharmaceutical were worth $248,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also made changes to their positions in RARE. Fortaleza Asset Management Inc. increased its position in shares of Ultragenyx Pharmaceutical by 148.5% in the first quarter. Fortaleza Asset Management Inc. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $111,000 after buying an additional 980 shares during the last quarter. Pacer Advisors Inc. increased its position in shares of Ultragenyx Pharmaceutical by 22.6% in the first quarter. Pacer Advisors Inc. now owns 3,037 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 560 shares during the last quarter. Strs Ohio increased its position in shares of Ultragenyx Pharmaceutical by 10.7% in the first quarter. Strs Ohio now owns 3,100 shares of the biopharmaceutical company’s stock valued at $210,000 after buying an additional 300 shares during the last quarter. Ameritas Investment Partners Inc. increased its position in shares of Ultragenyx Pharmaceutical by 3.7% in the first quarter. Ameritas Investment Partners Inc. now owns 3,226 shares of the biopharmaceutical company’s stock valued at $219,000 after buying an additional 115 shares during the last quarter. Finally, Massmutual Trust Co. FSB ADV acquired a new position in shares of Ultragenyx Pharmaceutical during the first quarter valued at $237,000. 95.25% of the stock is owned by institutional investors and hedge funds.
Ultragenyx Pharmaceutical Inc. (NASDAQ RARE) opened at 70.99 on Friday. The company has a 50-day moving average price of $62.37 and a 200 day moving average price of $67.89. The firm’s market capitalization is $3.00 billion. Ultragenyx Pharmaceutical Inc. has a 1-year low of $51.67 and a 1-year high of $91.35.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.63) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.71) by $0.08. During the same period in the previous year, the company earned ($1.35) EPS. Analysts expect that Ultragenyx Pharmaceutical Inc. will post ($7.04) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://stocknewstimes.com/2017/07/21/ultragenyx-pharmaceutical-inc-nasdaqrare-shares-bought-by-prudential-financial-inc.html.
Several research analysts have recently weighed in on the company. Jefferies Group LLC reaffirmed a “hold” rating and set a $68.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, July 14th. Zacks Investment Research raised Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Tuesday. BidaskClub raised Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Tuesday, June 20th. Cowen and Company reaffirmed an “outperform” rating on shares of Ultragenyx Pharmaceutical in a research note on Thursday, June 29th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $100.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Thursday, March 23rd. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $85.71.
In other Ultragenyx Pharmaceutical news, VP Theodore Alan Huizenga sold 480 shares of the business’s stock in a transaction on Friday, May 26th. The stock was sold at an average price of $57.46, for a total transaction of $27,580.80. Following the sale, the vice president now directly owns 9,366 shares in the company, valued at $538,170.36. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 9.20% of the stock is currently owned by insiders.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE).
Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
